Sign in
CompletedNo phase

Clinical Performance of SE-SPTM-PCR in Detecting Hcmv-miR-UL22A-5p After Hematopoietic Stem Cell Transplantation

Key facts

Who runs it
Ting YANG
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
60 people enrolled
Started
6 May 2021
Ended
18 Jun 2025
Type of study
Observational
Treatments tested
  • SE-SPTM-PCR microRNA assay
Record updated
18 September 2025

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Can take part
Show the full registry criteria (8)Hide the full registry criteria

Who can take part

  • Patients who received allogeneic hematopoietic stem cell transplantation (HSCT)
  • Availability of archived plasma samples collected within 100 days post-transplant
  • Documented CMV DNA testing results corresponding to the plasma sample
  • Age ≥ 18 years

Who cannot take part

  • Concurrent active infections with other viruses (e.g., EBV, HBV, HCV) at time of plasma collection
  • Patients who received investigational antiviral therapy within 2 weeks prior to sample collection
  • Lack of corresponding CMV DNA testing results
  • Inadequate volume or quality of archived plasma sample for analysis

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This study aims to evaluate the clinical performance of a novel microRNA-based detection platform, SE-SPTM-PCR, for identifying cytomegalovirus (CMV) infection after allogeneic hematopoietic stem cell transplantation (HSCT). Specifically, the study retrospectively analyzes plasma samples to determine whether hcmv-miR-UL22A-5p can serve as a sensitive and specific biomarker for CMV reactivation. Results will be compared to traditional CMV DNA testing methods.

The group in the trial

  • HSCT Patient Group

    This group includes patients who underwent allogeneic hematopoietic stem cell transplantation (HSCT). Archived plasma samples from these patients are used to evaluate the performance of the SE-SPTM-PCR platform for detecting hcmv-miR-UL22A-5p. Each sample has a corresponding CMV DNA test result, which serves as the reference standard for assessing the diagnostic accuracy of the microRNA-based detection method.

    Treatment: SE-SPTM-PCR microRNA assay

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Retrospective Clinical Validation of the SE-SPTM-PCR Platform for Hcmv-miR-UL22A-5p Detection in Monitoring Cytomegalovirus Infection After Allogeneic Hematopoietic Stem Cell Transplantation
Record updated
18 September 2025